NGM Biopharmaceuticals

Metabolic/fibrotic disease therapeutics

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
ILT2 and ILT4 (immunoglobulin-like transcript receptors 2 and 4)Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q3$0.6M$23M$57M$29Mreport ↗

NGM Biopharmaceuticals reported revenue of $0.58M, down 92.7% YoY, R&D spend of $22.94M, down 50.2% YoY, cash and equivalents of $56.93M, and a quarterly net burn of $28.8M for Q3 2023.

Figures only: this period's report disclosed no narrative text

View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q2$1.4M$32M$57M$38Mreport ↗
2023-Q1$2.3M$41M$72M$48Mreport ↗
2022-Q3$7.9M$46M$105M$47Mreport ↗
2022-Q2$8.3M$45M$65M$47Mreport ↗
2022-Q1$21M$43M$111M$32Mreport ↗
2021-Q3$19M$39M$147M$29Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$4.4M$118M$61M$142Mreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2022-FY$55M$181M$77M$163Mreport ↗
2021-FY$78M$162M$153M$120Mreport ↗